Galaxy Medicare Limited IPO Opens on Sep 10, 2025

• Total Issue Size - Up To 41,32,000 Equity Shares of ₹ 10 each • Fresh Issue - Up To 33,08,000 Equity Shares • Offer For Sale - Up To 8,24,000 Equity Shares • IPO Size - ₹ 22.31 Crore (At Upper Price Band) • Price Band - ₹ 51 - ₹ 54 Per Share • Lot Size – 2,000 Equity Shares Mumbai, Sep 09, 2025 – Galaxy Medicare Limited (The Company, Galaxy) is a manufacturer, trader, and exporter of medical devices, Plaster of Paris (POP) bandages, and surgical dressings, proposes to open its Initial Public Offering on Sep 10, 2025, aiming to raise ₹ 22.31 Crores (at upper price band) with shares to be listed on the NSE Emerge platform.

The issue size is 41,32,000 equity shares with a face value of ₹ 10 each with a price band of ₹ 51 - ₹ 54 Per Share.

Equity Share Allocation • Qualified Institutional Buyer – Not more than 80,000 Equity Shares • Non-Institutional Investors - Not less than 15,36,000 Equity Shares • Individual Investors - Not less than 23,08,000 Equity Shares • Market Maker - Up to 2,08,000 Equity Shares The net proceeds from the IPO will be utilized for funding Capital Expenditure requirement towards purchase of machinery for our existing manufacturing facility at Bhubaneshwar, Odisha, Funding the working capital requirements, and general corporate purposes. The issue will open on Wednesday, Sep 10, 2025 and will close on Friday, Sep 12, 2025.

The Book Running Lead Manager to the Issue is Affinity Global Capital Market Private Limited, and the Registrar is Cameo Corporate Services Limited.

Mr. Dillip Kumar Das, Managing Director of Galaxy Medicare Limited expressed “Our journey of over three decades in the healthcare and medical devices industry has been driven by our commitment to quality, innovation, and customer trust. Galaxy Medicare Limited has steadily grown its presence across multiple business verticals, including our flagship brands, contract manufacturing, institutional sales, exports, and trading. With a well-diversified portfolio of medical devices, plaster of Paris bandages, and surgical dressings marketed under 27 registered trademarks, we have established a strong reputation in India and international markets.

The upcoming IPO will enable us to strengthen our manufacturing capabilities through the purchase of advanced machinery at our Bhubaneswar facility, which will enhance our production efficiency and product quality. Additionally, the proceeds will support our working capital requirements, enabling us to meet growing demand and expand our institutional and export business further. We believe this step will position us for sustained growth while contributing meaningfully to the healthcare sector, supporting both domestic and global healthcare needs.” Ms. Shruti Bhalotia, Director of Affinity Global Capital Market Private Limited “We are pleased to act as the Book Running Lead Manager for the upcoming IPO of Galaxy Medicare Limited, a well-established player in the medical devices and healthcare products industry. The company has demonstrated consistent growth over three decades, supported by a diversified business model that includes flagship brands, contract manufacturing, institutional sales, exports, and trading.

Given the increasing demand for quality medical devices and surgical products driven by rising healthcare awareness and government initiatives, Galaxy Medicare is well-positioned to capitalize on market opportunities. The proposed utilization of IPO proceeds for enhancing manufacturing capabilities and supporting working capital reflects a prudent strategy to drive operational efficiency and business expansion. We believe the company’s strong brand presence, wide product portfolio, and global market reach provide a comprehensive foundation for sustainable growth.” About Galaxy Medicare Limited Galaxy Medicare Limited is a manufacturer, trader, and exporter of medical devices, Plaster of Paris (POP) bandages, and surgical dressings. With over three decades of expertise, the company operates through multiple verticals: its own Flagship Brands, Contract Manufacturing, Institutional sales to Government Health Departments.

The Company’s portfolio, marketed under 27 registered trademarks including POP BAND, G CAST, GYPSOSOFT, CARETAPE, CAREPORE & more, is widely accepted by the medical fraternity across India and abroad. The Company serves central and state governments, corporate hospitals, and private players while exporting to markets such as UK, Germany, Burundi, Malaysia, Bangladesh and Nepal.

In FY25, The Company achieved a Revenue of ₹ 3,920.16 Lakhs, EBITDA of ₹ 458.42 Lakhs & PAT of ₹ 337.04 Lakhs.

(Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR

(This content is sourced from a syndicated feed and is published as received. The Tribune assumes no responsibility or liability for its accuracy, completeness, or content.)